two thousand and five two respected academics lisa kos grove of you must boston and sheldon prim skee of tufts released their investigation into conflicts of interest between d.s.m. four panel members and the pharmaceutical industry i think the data really speak for themselves the strongest statistics include the panel members for the mood disorders and schizophrenia and psychotic disorders one hundred percent of those panel members and yes that's right every single panel member has financial says with the pharmaceutical industry and if you look at it in terms of the sheer amount of money the antidepressant market and the anti-psychotic markets are the fourth and fifth leading therapy classes of drugs with annual sales of twenty billion in fourteen billion respectively there are one hundred seventy d.s.m. panel members that's the total inclusive of all the working groups of those one hundred seventy panel members fifty six percent had. at least one financial says yes or the pharmaceutical company. the d.s.m. decision makers actions over the last thirty years have reverberated in sad and profou

two thousand and five two respected academics lisa kos grove of you must boston and sheldon prim skee of tufts released their investigation into conflicts of interest between d.s.m. four panel members and the pharmaceutical industry i think the data really speak for themselves the strongest statistics include the panel members for the mood disorders and schizophrenia and psychotic disorders one hundred percent of those panel members and yes that's right every single panel member has financial cessations with the pharmaceutical industry and if you look at it in terms of the sheer amount of money the antidepressant market and the anti-psychotic markets are the fourth and fifth leading therapy classes of drugs with annual sales of twenty billion and fourteen billion respectively there are one hundred seventy d.s.m. panel members that's the total inclusive of all the working groups of those one hundred seventy panel members fifty six percent had. at least one financial says yes or the pharmaceutical company. the d.s.n. decision makers actions over the last thirty years have reverberated in sad and